Teva Pharmaceutical Feed

	Est. tid*
2027-01-28	N/A	Bokslutskommuniké 2026
2026-11-05	13:00	Kvartalsrapport 2026-Q3
2026-07-30	13:00	Kvartalsrapport 2026-Q2
2026-05-07	13:00	Kvartalsrapport 2026-Q1
2026-01-28	-	Bokslutskommuniké 2025
2025-11-05	-	Kvartalsrapport 2025-Q3
2025-07-30	-	Kvartalsrapport 2025-Q2
2025-06-05	-	Årsstämma
2025-05-07	-	Kvartalsrapport 2025-Q1
2025-01-29	-	Bokslutskommuniké 2024
2024-11-06	-	Kvartalsrapport 2024-Q3
2024-07-31	-	Kvartalsrapport 2024-Q2
2024-06-06	-	Årsstämma
2024-05-08	-	Kvartalsrapport 2024-Q1
2024-01-31	-	Bokslutskommuniké 2023
2023-11-08	-	Kvartalsrapport 2023-Q3
2023-08-02	-	Kvartalsrapport 2023-Q2
2023-06-15	-	Årsstämma
2023-05-10	-	Kvartalsrapport 2023-Q1
2023-02-08	-	Bokslutskommuniké 2022
2022-11-03	-	Kvartalsrapport 2022-Q3
2022-07-27	-	Kvartalsrapport 2022-Q2
2022-06-23	-	Årsstämma
2022-05-03	-	Kvartalsrapport 2022-Q1
2022-02-09	-	Bokslutskommuniké 2021
2021-10-27	-	Kvartalsrapport 2021-Q3
2021-07-28	-	Kvartalsrapport 2021-Q2
2021-06-14	-	Årsstämma
2021-04-28	-	Kvartalsrapport 2021-Q1
2021-02-10	-	Bokslutskommuniké 2020
2020-11-05	-	Kvartalsrapport 2020-Q3
2020-08-05	-	Kvartalsrapport 2020-Q2
2020-06-09	-	Årsstämma
2020-05-07	-	Kvartalsrapport 2020-Q1
2020-02-12	-	Bokslutskommuniké 2019
2019-11-07	-	Kvartalsrapport 2019-Q3
2019-08-07	-	Kvartalsrapport 2019-Q2
2019-06-11	-	Årsstämma

Land	Israel
Sektor	Hälsovård
Industri	Läkemedel & Handel

2026-03-19 21:30:00 Teva Releases Q1 2026 Aide Memoire

2026-03-19 21:30:00 Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026

2026-03-03 23:00:00 Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug 32,00 USD | -6,71%

2026-02-24 22:30:00 Teva to Present at the Upcoming Investor Conferences in March 33,70 USD | -0,59%

2026-02-20 20:43:26 U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults 34,30 USD | +1,78%

2026-02-17 12:00:00 Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease 35,00 USD | +3,24%

2026-01-28 13:00:00 Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential 32,00 USD | -0,62%

2026-01-27 14:00:00 Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’ 32,20 USD | +0,63%

2026-01-14 23:02:43 AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine 32,20 USD | -0,62%

2026-01-12 00:00:00 Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation 32,80 USD | +0,61%

2026-01-11 23:00:00 Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

2026-01-05 22:30:00 Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference 30,70 USD | +0,99%

2025-12-24 14:36:26 S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive 31,70 USD | +1,93%

2025-12-19 09:40:00 Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea® 30,20 USD | +0,67%

2025-12-12 22:30:00 Teva Releases Q4 2025 Aide Memoire 30,20 USD | +3,78%

2025-12-12 22:30:00 Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026 30,20 USD | +3,78%

2025-12-09 14:00:00 Teva Pharmaceuticals Submits New Drug Application to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults 28,50 USD | -0,70%

2025-11-26 01:06:11 Teva erhält Zulassung der Europäischen Kommission für PONLIMSI® (Denosumab), ein Biosimilar zu Prolia®, und DEGEVMA® (Denosumab), ein Biosimilar zu Xgeva® 25,50 USD | +2,82%

2025-11-26 01:06:11 Teva obtient les autorisations de la Commission européenne pour PONLIMSI® (dénosumab), biosimilaire de Prolia® et DEGEVMA® (dénosumab), biosimilaire de Xgeva® 25,50 USD | +2,82%

2025-11-25 14:10:27 Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva® 24,80 USD | +1,64%

2025-11-21 22:30:00 Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December 24,20 USD | -0,82%

2025-11-08 00:00:00 AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living

2025-11-05 13:00:00 Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS 24,00 USD | +17,94%

2025-10-31 21:30:00 Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in November 20,30 USD | +0,74%

2025-10-21 22:19:19 Teva und Prestige Biopharma schließen Lizenzvereinbarung für die Vermarktung von Tuznue® in Europa 19,20 USD | -1,03%

2025-10-21 22:19:19 Teva et Prestige Biopharma concluent un accord de licence pour la commercialisation de Tuznue® en Europe 19,20 USD | -1,03%

2025-10-20 22:30:00 Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe 19,40 USD | +0,26%

2025-10-10 21:00:22 FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder 20,30 USD | -1,22%

2025-09-25 22:30:00 Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025 19,00 USD | -2,06%

2025-09-25 22:30:00 Teva Releases Q3 2025 Aide Memoire 19,00 USD | -2,06%

2025-09-21 04:16:00 Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction

2025-09-21 04:15:00 New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

2025-09-16 22:30:00 Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting 18,65 USD | -4,85%

2025-09-02 22:30:00 Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September 18,15 USD | -1,09%

2025-08-28 14:30:00 Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss 18,05 USD | -1,10%

2025-06-26 22:30:00 Teva Releases Q2 2025 Aide Memoire 17,05 USD | +0,59%

2025-06-25 22:30:00 Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025 16,95 USD | -1,17%

2025-06-24 13:23:46 Les données définitives de l’étude PEARL menée par Teva en conditions réelles confirment l’efficacité à long terme d’AJOVY® (frémanézumab) pour la prévention de la migraine chronique et épisodique 17,15 USD | -0,58%

2025-06-24 13:23:46 Abschließende Daten aus der realen PEARL-Studie von Teva untermauern die langfristige Wirksamkeit von AJOVY® (fremanezumab) für die Prävention chronischer und episodischer Migräne 17,15 USD | -0,58%

2025-06-23 09:00:00 Final Data from Teva’s PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine 17,25 USD | +0,58%

2025-06-03 23:30:00 Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer 17,25 USD | +0,58%

2025-06-03 13:16:02 Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement 17,15 USD | +3,31%

2025-05-31 03:05:00 New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025

2025-05-29 14:00:00 Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day 17,60 USD | -2,49%

2025-05-27 23:30:00 Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA 18,05 USD | +3,74%

2025-05-27 22:30:00 Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June 17,40 USD | +5,45%

2025-05-27 14:30:00 Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma 17,40 USD | +5,45%

2025-05-22 19:56:26 Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes 16,50 USD | -2,08%

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Teva Pharmaceutical

Kalender

Beskrivning

Vem äger bolaget?

Teva Pharmaceutical

Kalender

Beskrivning

Vem äger bolaget?

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden